A Conversation with an MPN Specialist: Myelofibrosis

MPN Advocacy & Education International was joined by Dr. John Mascarenhas, Mount Sinai, to provide updates and answer questions about myelofibrosis.

TIMESTAMPS
00:00 A Conversation with an MPN Specialist: Myelofibrosis
12:32 Have you seen any patients who have CLL and also MF? If so, how do you typically treat that patient?
16:24 What is the indicative longest-term data on MF patients who have responded very positively to clinical trial drugs early and for a few years?
20:14 What is the typical amount of time a person in their late 60s with MF grade 2 with mild symptoms remains in the watch-and-wait phase before needing to start medication?
25:13 Can you tell the difference between someone who has progressed to myelofibrosis from polycythemia vera or essential thrombocythemia?
28:37 What are the differences between primary and secondary myelofibrosis in terms of treatment and prognosis?
30:37 Five years ago my PV progressed to MF, JAK2, and ASXL gene mutations, and I was told the only cure would be a stem cell transplant. I am experiencing zero symptoms and am very active. I am about to turn 70 years of age and uncertain if I should really look into a transplant?
34:11 I am 75 years old and was diagnosed with PV almost 25 years ago and progressed to MF three years ago. I am currently taking 20mg of Jakafi daily. Is it typical to be symptom-free for this long?
37:55 I've been on Pegasys and wondering if it's capable of reversing myelofibrosis?
42:42 Thoughts on progression
46:42 Can you talk about the clinical trials that are investigating monoclonal antibodies?
50:52 Do have conversations with your patients about limiting stress and making healthy day-to-day changes to help with their care and disease?